Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2004-01-28
2008-11-18
Russel, Jeffrey E (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S400000, C424S447000, C424S450000, C514S777000, C514S786000, C514S938000, C530S324000
Reexamination Certificate
active
07452864
ABSTRACT:
Use of the antimicrobial cathelicidin peptide ll-37, N-terminal fragments of LL-37 or extended sequences of LL-37 having 1-3 amino acids in the C-terminal end, for stimulating proliferation of epithalial and stromal cells and thereby healing of wounds, such as chronic ulcers. The cytotoxic effect of LL-37 may be reduced by including a bilayer-forming polar lipid, especially a digalactosyldiacylglycerol, in pharmaceutical compositions and growth media comprising LL-37.
REFERENCES:
patent: 5925534 (1999-07-01), Miki et al.
patent: 6255282 (2001-07-01), Jaynes
patent: 2002/0072495 (2002-06-01), Chertov et al.
patent: 2003/0022829 (2003-01-01), Maury et al.
patent: 0 935 965 (1999-08-01), None
patent: 1 358 888 (2003-11-01), None
patent: WO-96/09322 (1996-03-01), None
patent: WO 99/44586 (1999-09-01), None
patent: WO-00/57895 (2000-10-01), None
patent: WO-02/095076 (2002-11-01), None
Pestonjamasp et al. Antimicrobial Peptides Are Effectors of Wound Repair. Wound Repair and Regeneration. Mar.-Apr. 2001, vol. 9, No. 2, p. 158, Abstract No. 76.
Yatomi et al. Sphigosine 1-phosphate as a major bioactive lysophopholipid . . . Blood. Nov. 15, 2000, vol. 96, No. 10, pp. 3431-3438.
Heilborn et al. The cathelicidin Anti-Microbial Peptide LL-37 is Involved . . . Journal of Investigative Dermatology. 2003, vol. 120, pp. 379-389.
Koczulla et al. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. Journal of Clinical Investigation. 2003, vol. 111, pp. 1665-1672.
Larrick et al., Immunotechnology, vol. 1, 1995, pp. 65-72.
Gutsmann et al., Biophysical Journal, vol. 80, Jun. 2001, pp. 2935-2945.
Larrick et al., Antimicrobial Agents and Chemotherapy, vol. 37, No. 12, 1993, pp. 2534-2539.
Saiman et al., Antimicrobial Agents and Chemotherapy, vol. 45, No. 10, 2001, pp. 2838-2844.
Sorensen et al., The Journal of Biochemistry, vol. 274, No. 32, 1999, pp. 22445-22451.
Wang et al., The Journal of Biological Chemistry, vol. 273, No. 50, 1998, pp. 33115-33118.
Pestonjamasp et al., Wound Repair and Regeneration, vol, 9, No. 2, 2001, p. 158.
R. Bals,Respiratory Res., vol. 1, No. 3, pp. 141-150, (2000).
R. Dorschner et al.,J. Invest. Dermatol., vol. 117, No. 1, pp. 91-97, (2001).
M. F. Nilsson,Thesis, Karolinska Instituet, Stockholm (2001).
M. Zasloff,Nature, vol. 415, pp. 389-395, (2002).
Bogentoft Conny
Carlsson Anders
Heilborn Johan
Ståhle-Bäckdahl Mona
Birch Stewart Kolasch & Birch, LLP.
Lipopeptide AB
Russel Jeffrey E
LandOfFree
Use of the cathelicidin LL-37 and derivatives thereof for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of the cathelicidin LL-37 and derivatives thereof for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of the cathelicidin LL-37 and derivatives thereof for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4023548